For example, the recent FDA approved pazopanib (Votrient), a multi target receptor tyrosine kinase inhibitor (TKI) against PDGFR α/β, VEGFR-1, -2, -3 and c-kit [88], as well as MET/HGF inhibitors (monoclonal antibodies against HGF and selective MET tyrosine kinase inhibitors) [89] and the humanized monoclonal antibody (mAb) against VEGF-A Bevacizumab (Avastin) [90] have been validated to target the same molecules expressed by both tumor cells and CAFs. Here, VEGFA is linked to neoplasm.